BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/25/2021 6:50:38 AM | Browse: 395 | Download: 759
 |
Received |
|
2021-03-23 20:21 |
|
Peer-Review Started |
|
2021-03-23 20:23 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-30 04:59 |
|
Revised |
|
2021-08-06 08:43 |
|
Second Decision |
|
2021-10-22 06:45 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-10-25 02:08 |
|
Articles in Press |
|
2021-10-25 02:08 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-11-23 12:34 |
|
Publish the Manuscript Online |
|
2021-11-25 06:50 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Zvonimir Ostojic, Ana Ostojic, Josko Bulum and Anna Mrzljak |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ana Ostojic, MD, PhD, Senior Postdoctoral Fellow, Department of Gastroenterology and Hepatology, University Hospital Center, Kispaticeva 12, Zagreb 10000, Croatia. ostojicana.zg@gmail.com |
| Key Words |
End-stage liver disease; Cirrhosis; Liver transplantation; Coronary artery disease; Percutaneous coronary intervention; Antiplatelet therapy |
| Core Tip |
Dual antiplatelet therapy (DAPT) is necessary after a percutaneous coronary intervention (PCI). However, it could result in severe consequences in patients with liver cirrhosis. Based on novel findings, liver cirrhosis does not necessarily lead to a significant increase in bleeding complications. Patients with cirrhosis who have the highest bleeding risk are those with severe thrombocytopenia and elevated portal pressure. Despite the lack of solid evidence for DAPT in patients with cirrhosis, trials investigating one month of DAPT duration after PCI can be implemented in cirrhotic patients. Before PCI, functional assessment of coronary artery disease severity should be performed to avoid unnecessary interventions. |
| Publish Date |
2021-11-25 06:50 |
| Citation |
Ostojic Z, Ostojic A, Bulum J, Mrzljak A. Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease. World J Cardiol 2021; 13(11): 599-607 |
| URL |
https://www.wjgnet.com/1949-8462/full/v13/i11/599.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v13.i11.599 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
